These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 2151271

  • 1. A new longer-acting LHRH analog depot: preliminary results of a Dutch open phase II clinical study on a 10.8 mg Zoladex 3-monthly depot.
    Dijkman GA, Fernandez del Moral P, Plasman JW, Pull HC, van der Meijden AP, Debruyne FM, Hutchinson FG, Furr BJ.
    Eur Urol; 1990; 18 Suppl 3():22-5. PubMed ID: 2151271
    [Abstract] [Full Text] [Related]

  • 2. Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer.
    Ahmann FR, Citrin DL, deHaan HA, Guinan P, Jordan VC, Kreis W, Scott M, Trump DL.
    J Clin Oncol; 1987 Jun; 5(6):912-7. PubMed ID: 2953870
    [Abstract] [Full Text] [Related]

  • 3. A new extra long acting depot preparation of the LHRH analogue Zoladex. First endocrinological and pharmacokinetic data in patients with advanced prostate cancer.
    Dijkman GA, del Moral PF, Plasman JW, Kums JJ, Delaere KP, Debruyne FM, Hutchinson FJ, Furr BJ.
    J Steroid Biochem Mol Biol; 1990 Dec 20; 37(6):933-6. PubMed ID: 2149507
    [Abstract] [Full Text] [Related]

  • 4. An LH-RH analogue (Zoladex) in the management of carcinoma of the prostate: a preliminary report comparing daily subcutaneous injections with monthly depot injections.
    Robinson MR, Denis L, Mahler C, Walker K, Stitch R, Lunglmayr G.
    Eur J Surg Oncol; 1985 Jun 20; 11(2):159-65. PubMed ID: 3159598
    [Abstract] [Full Text] [Related]

  • 5. Treatment of patients with advanced cancer of the prostate using a slow-release (depot) formulation of the LHRH agonist ICI 118630 (Zoladex).
    Walker KJ, Turkes AO, Turkes A, Zwink R, Beacock C, Buck AC, Peeling WB, Griffiths K.
    J Endocrinol; 1984 Nov 20; 103(2):R1-4. PubMed ID: 6238116
    [Abstract] [Full Text] [Related]

  • 6. [Chemical castration using a depot LHRH-agonist as a palliative therapy concept in prostatic carcinoma--clinical, endocrinological and experimental studies].
    Kuber W, Treu T, Kratzik C, Girsch E, Zeillinger R, Spona J.
    Wien Klin Wochenschr; 1990 Nov 09; 102(21):640-7. PubMed ID: 2148044
    [Abstract] [Full Text] [Related]

  • 7. LH-RH agonist, Zoladex (Goserelin), depot formulation in the treatment of prostatic cancer. Randomized dose-finding trial in Japan.
    Kotake T, Usami M, Sonoda T, Matsuda M, Okajima E, Osafune M, Isurugi K, Akaza H, Saitoh Y.
    Am J Clin Oncol; 1988 Nov 09; 11 Suppl 2():S108-11. PubMed ID: 2977262
    [Abstract] [Full Text] [Related]

  • 8. Long-term therapy with a depot luteinizing hormone-releasing hormone analogue (Zoladex) in patients with advanced prostatic carcinoma.
    Debruyne FM, Denis L, Lunglmayer G, Mahler C, Newling DW, Richards B, Robinson MR, Smith PH, Weil EH, Whelan P.
    J Urol; 1988 Oct 09; 140(4):775-7. PubMed ID: 2971119
    [Abstract] [Full Text] [Related]

  • 9. Preliminary report on use of depot formulation of LHRH analogue ICI 118630 (Zoladex) in patients with prostatic cancer.
    Ahmed SR, Grant J, Shalet SM, Howell A, Chowdhury SD, Weatherson T, Blacklock NJ.
    Br Med J (Clin Res Ed); 1985 Jan 19; 290(6463):185-7. PubMed ID: 3155636
    [Abstract] [Full Text] [Related]

  • 10. Treatment of advanced prostatic carcinoma with a slow release depot LHRH analogue (Zoladex depot).
    Lukkarinen O, Kontturi M.
    Scand J Urol Nephrol Suppl; 1988 Jan 19; 110():109-12. PubMed ID: 2973121
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetic and endocrinological parameters of a slow-release depot preparation of the GnRH analogue ICI 118630 (zoladex) compared with a subcutaneous bolus and continuous subcutaneous infusion of the same drug in patients with prostatic cancer.
    Perren TJ, Clayton RN, Blackledge G, Bailey LC, Holder G, Lynch SS, Arkell DG, Cottam J, Farrar D, Young CH.
    Cancer Chemother Pharmacol; 1986 Jan 19; 18(1):39-43. PubMed ID: 2944668
    [Abstract] [Full Text] [Related]

  • 12. A randomised trial comparing the safety and efficacy of the Zoladex 10.8-mg depot, administered every 12 weeks, to that of the Zoladex 3.6-mg depot, administered every 4 weeks, in patients with advanced prostate cancer. The Dutch South East Cooperative Urological Group.
    Dijkman GA, Debruyne FM, Fernandez del Moral P, Plasman JW, Hoefakker JW, Idema JG, Sykes M.
    Eur Urol; 1995 Jan 19; 27(1):43-6. PubMed ID: 7744141
    [Abstract] [Full Text] [Related]

  • 13. Zoladex (ICI 118,630): clinical trial of new luteinizing hormone-releasing hormone analog in metastatic prostatic carcinoma.
    Murphy GP, Greco JM, Chin JL, Huben RP, Scott M, deHaan HA.
    Urology; 1987 Feb 19; 29(2):185-90. PubMed ID: 2949417
    [Abstract] [Full Text] [Related]

  • 14. [Clinical effect of slow release (depot) formulation of the LH-RH analogue ICI 118630 (Zoladex) in patients with prostatic carcinoma].
    Usami M, Kotake T, Matsuda M, Okajima E, Osafune M, Sonoda T.
    Hinyokika Kiyo; 1987 Jan 19; 33(1):141-50. PubMed ID: 2953179
    [Abstract] [Full Text] [Related]

  • 15. Long term therapy with a depot LHRH analogue (Zoladex) in patients with advanced prostatic cancer.
    Denis L, Keuppens F, Mahler C, Debruyne FM, Weil EH, Lunglmayr G, Newling D, Robinson MR, Richards B, Smith PH.
    Prog Clin Biol Res; 1987 Jan 19; 243A():221-7. PubMed ID: 2958852
    [No Abstract] [Full Text] [Related]

  • 16. Renewal timing of long-acting depot luteinizing hormone-releasing hormone agonist (Zoladex) is critical in the treatment of hormone-dependent rat prostatic carcinoma (R3327-H).
    Geldof AA, de Voogt HJ, Rao BR.
    Prostate; 1987 Jan 19; 11(3):281-90. PubMed ID: 2960958
    [Abstract] [Full Text] [Related]

  • 17. Testosterone and gonadotrophin profiles in patients on daily or monthly LHRH analogue ICI 118630 (Zoladex) compared with orchiectomy.
    Grant JB, Ahmed SR, Shalet SM, Costello CB, Howell A, Blacklock NJ.
    Br J Urol; 1986 Oct 19; 58(5):539-44. PubMed ID: 2946356
    [Abstract] [Full Text] [Related]

  • 18. Treatment of prostatic cancer by monthly injections of an LHRH-analogue depot.
    Hjertberg H, Varenhorst E, Svensson M, Kågedal B, Nordenskjöld B.
    Acta Oncol; 1988 Oct 19; 27(4):361-4. PubMed ID: 2974290
    [Abstract] [Full Text] [Related]

  • 19. [Clinical effects of a 3-month formulation LH-RH agonist (Zoladex LA 10.8 mg depot) in patients with prostate cancer].
    Kotake T, Akaza H, Usami M, Naito S, Kanetake H, Taguchi T, Tsukagoshi S, Koiso K.
    Hinyokika Kiyo; 2001 May 19; 47(5):349-61. PubMed ID: 11433759
    [Abstract] [Full Text] [Related]

  • 20. Zoladex treatment of symptomatic prostatic carcinoma.
    Holdaway IM, Ibbertson HK, Croxson MS, Harvey V, Boulton J, Knox BS.
    Am J Clin Oncol; 1988 May 19; 11 Suppl 2():S123-6. PubMed ID: 2977267
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.